A Phase 2A Clinical Trial of EPI-743 (Vincerinone) on Visual Function in Friedreich's Ataxia Patients With Point Mutations

Trial Profile

A Phase 2A Clinical Trial of EPI-743 (Vincerinone) on Visual Function in Friedreich's Ataxia Patients With Point Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 21 Apr 2016 Results assessing neurologic functions presented at the 68th Annual Meeting of the American Academy of Neurology
    • 02 Apr 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top